Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia

Am J Hematol. 2023 Jun;98(6):E142-E144. doi: 10.1002/ajh.26907. Epub 2023 Mar 16.

Authors

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁴ Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

PMID: 36877196
DOI: 10.1002/ajh.26907

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Burkitt Lymphoma*
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Receptors, Cytokine / genetics

Substances

CRLF2 protein, human
Receptors, Cytokine

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States